Literature DB >> 17486579

Cerebral involvement in myotonic dystrophies.

Giovanni Meola1, Valeria Sansone.   

Abstract

Myotonic dystrophy types 1 (DM1) and 2 (DM2) are similar yet distinct autosomal-dominant disorders characterized by muscle weakness, myotonia, cataracts, and multiple organ involvement, including the brain. One key difference between DM1 and DM2 is that a congenital form has been described for DM1 only. Expression of RNA transcripts containing pathogenic repeat lengths produces defects in alternative splicing of multiple RNAs, sequesters specific repeat-binding proteins, and ultimately leads to developmentally inappropriate splice products for a particular tissue. Whether brain pathology in its entirety in adult DM1 and DM2 is caused by interference in RNA processing remains to be determined. This review focuses on the similarities and differences between DM1 and DM2 with respect to neuropsychological, neuropathological, and neuroimaging data relating to cerebral involvement, with special emphasis on the clinical relevance and social consequences of such involvement.

Entities:  

Mesh:

Year:  2007        PMID: 17486579     DOI: 10.1002/mus.20800

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  71 in total

1.  Myotonic dystrophies as a brain disorder.

Authors:  Giovanni Meola
Journal:  Neurol Sci       Date:  2010-10-06       Impact factor: 3.307

2.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 3.  Therapeutics development in myotonic dystrophy type 1.

Authors:  Erin Pennock Foff; Mani S Mahadevan
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

Review 4.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

Review 5.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

6.  Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1.

Authors:  Jeffrey R Wozniak; Bryon A Mueller; Kelvin O Lim; Laura S Hemmy; John W Day
Journal:  J Neurol Sci       Date:  2014-04-13       Impact factor: 3.181

Review 7.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

8.  Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study.

Authors:  A Modoni; G Silvestri; M Gabriella Vita; D Quaranta; P A Tonali; C Marra
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

9.  Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates.

Authors:  Stefan Winblad; Christer Jensen; Jan-Eric Månsson; Lena Samuelsson; Christopher Lindberg
Journal:  Behav Brain Funct       Date:  2010-05-19       Impact factor: 3.759

10.  Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy.

Authors:  Konstantinos Charizanis; Kuang-Yung Lee; Ranjan Batra; Marianne Goodwin; Chaolin Zhang; Yuan Yuan; Lily Shiue; Melissa Cline; Marina M Scotti; Guangbin Xia; Ashok Kumar; Tetsuo Ashizawa; H Brent Clark; Takashi Kimura; Masanori P Takahashi; Harutoshi Fujimura; Kenji Jinnai; Hiroo Yoshikawa; Mário Gomes-Pereira; Geneviève Gourdon; Noriaki Sakai; Seiji Nishino; Thomas C Foster; Manuel Ares; Robert B Darnell; Maurice S Swanson
Journal:  Neuron       Date:  2012-08-09       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.